Case Report

Gabapentin Adjunctive Therapy in Neuropathic Pain States

Rosner, Howard M.D.; Rubin, Lori M.D.; Kestenbaum, Alan M.D.

Author Information

Pain Management Service, Department of Anesthesiology, New York Hospital, Cornell Medical Center, New York, New York, U.S.A.

Manuscript submitted June 14, 1995; first revision received August 22, 1995; second revision received November 28, 1995; accepted for publication January 3, 1996.

Address correspondence and reprint requests to Dr. H. Rosner at Pain Management Service, Department of Anesthesiology, New York Hospital, 525 E. 68 St., New York, NY 10021, U.S.A.

The Clinical Journal of Pain 12(1):p 56-58, March 1996.

Abstract

Objective: 

This is a report of a trial of the new antiepileptic agent gabapentin in patients with intractable neuropathic pain.

Design: 

A case series of patients with a diagnosis of neuropathic pain whose previous management was inadequate were given oral gabapentin in increasing doses and were followed for a minimum of 2 months, monitored for efficacy and side effects.

Setting: 

An outpatient pain management center located within a major university medical center.

Patients: 

Convenience sample of patients referred for management of intractable neuropathic pain.

Interventions: 

Simplification of existing pharmacologic management, addition of gabapentin, and attempted reduction of opiate analgesic doses.

Main Outcome Measures: 

Patient self-reports and pain scores in successive office visits.

Results: 

Gabapentin provides analgesic activity for patients with neuropathic pain and has the advantage of a low side effect profile and drug toxicity.

© Lippincott-Raven Publishers

Full Text Access for Subscribers:

Not a Subscriber?

Buy
Request Permissions

You can read the full text of this article if you:

Access through Ovid